Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma

Next Previous
Trial Profile

A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs QXL 138AM (Primary)
  • Indications Advanced breast cancer; Gastrointestinal cancer; Liver cancer; Lung cancer; Male breast cancer; Multiple myeloma; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cancer; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Nammi Therapeutics

Most Recent Events

  • 16 Jun 2022 New trial record
  • 13 Jun 2022 According to a Nammi Therapeutics media release, the company expect to file IND with the FDA to allow initiation of clinical studies this year.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top